10-Q: Biodesix Q2 Revenue Jumps 12% Amid Nasdaq Delisting Threat

Biodesix, Inc. reported a 12% increase in second-quarter revenue, driven by strong growth in diagnostic tests and development services, but faces a Nasdaq delisting notice and increased net loss for the quarter.

Summary

• Total revenue for the second quarter ended June 30, 2025, increased by 12% to $20.0 million compared to $17.9 million in the prior year period.
• Diagnostic Tests revenue grew 8% to $17.9 million, primarily due to increased tests delivered for Nodify Lung Nodule Risk Assessment.
• Development Services revenue surged 53% to $2.1 million, driven by new agreements and an expanding book of business.
• Gross margin improved by 150 basis points to 80% for the second quarter 2025, attributed to growth in lung diagnostic testing and workflow optimization.
• Operating expenses (excluding direct costs) increased 15% to $25.7 million, mainly due to planned expansion of the sales team.
• Net loss for the second quarter 2025 increased 6% to $11.5 million, compared to $10.8 million in the same period last year.
• Cash and cash equivalents decreased to $20.7 million as of June 30, 2025, from $26.2 million at December 31, 2024.
• The company received a Nasdaq delisting notice on March 24, 2025, for failing to meet the minimum $1.00 bid price requirement, with a compliance date of September 22, 2025.
• Biodesix drew the $10.0 million Tranche C loan from the Perceptive Term Loan Facility on May 8, 2025, extending its availability through December 31, 2025.

Sentiment

Score: 4

Explanation: While revenue growth and gross margin improvement are positive, the increasing net loss in the quarter, declining cash reserves, and the significant Nasdaq delisting notice create substantial financial and operational uncertainty. The regulatory environment for LDTs also presents a major overhang.

Positives

• Total revenue increased 12% for the second quarter and 16% for the six months ended June 30, 2025, demonstrating strong top-line growth.
• Diagnostic Tests revenue grew 8% in Q2 2025, driven by increased adoption of Nodify Lung Nodule Risk Assessment tests.
• Development Services revenue showed significant growth of 53% in Q2 2025, reflecting success in securing new agreements and expanding business.
• Gross margin improved by 150 basis points to 80% in Q2 2025, indicating better cost efficiency and favorable business mix.
• Net loss for the six months ended June 30, 2025, decreased by 8% to $22.6 million, compared to $24.4 million in the prior year period, showing an improvement in year-to-date profitability.
• Patient enrollment requirements for the ALTITUDE study were reached in July 2025, a key milestone for Nodify CDT and XL2 tests.
• A new master collaborative research agreement (MCRA) was announced with Memorial Sloan Kettering Cancer Center (MSK) for oncology biomarker assays, indicating continued innovation and partnerships.

Negatives

• Net loss for the second quarter 2025 increased 6% to $11.5 million, indicating worsening quarterly profitability.
• Cash and cash equivalents decreased to $20.7 million as of June 30, 2025, from $26.2 million at December 31, 2024, reflecting ongoing cash burn.
• Received a Nasdaq delisting notice on March 24, 2025, due to the common stock closing below the minimum $1.00 bid price for 30 consecutive business days, posing a significant risk to liquidity and market price.
• Operating expenses (excluding direct costs) increased 15% in Q2 2025, primarily due to increased sales and marketing costs, contributing to the higher net loss.
• The company continues to operate at a net loss and has not yet generated positive cash flows from operations.

Risks

• Inability to achieve or sustain profitability.
• Failure to attain significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies for diagnostic tests.
• Difficulties managing growth, which could disrupt operations.
• Failure to retain sales and marketing personnel, or to increase sales and marketing capabilities to generate revenue growth.
• Significant fluctuations in operating results, potentially causing results to fall below expectations or guidance.
• Reliance on third-party suppliers, including courier services and single-source suppliers, making the company vulnerable to supply problems and price fluctuations.
• Security or data privacy breaches or other unauthorized or improper access to information systems.
• Inability to compete successfully with competition from many sources, including larger companies.
• Cost-containment efforts of customers, purchasing groups, and integrated delivery networks materially affecting sales and profitability.
• General economic and financial market conditions, including enhanced U.S. tariffs, import/export restrictions, or other trade barriers.
• Need to raise additional capital to fund existing operations, develop platforms, commercialize new diagnostic tests, or expand operations.
• Uncertainty of insurance coverage and reimbursement status of newly approved diagnostic tests.
• Future healthcare reform measures that could hinder or prevent the commercial success of diagnostic tests.
• Failure to comply with ongoing FDA or other domestic and foreign regulatory authority requirements, or unanticipated problems with diagnostic tests, causing them to be subject to restrictions or withdrawal from the market.
• Legal proceedings initiated by third parties alleging intellectual property infringement.
• Volatility of the trading price of common stock.
• No assurance that common stock will continue to trade on The Nasdaq Stock Market LLC or another national securities exchange, particularly given the current non-compliance with the minimum bid price requirement.
• Inaccurate estimates or judgments relating to critical accounting policies.
• FDA phasing out its general policy of enforcement discretion and regulating laboratory developed tests (LDTs) as medical devices, which could subject the company's tests to extensive and costly regulatory requirements.
• Legal challenges to the FDA's authority to regulate LDTs as medical devices, creating regulatory uncertainty.
• Legislative or regulatory reforms that could make it more difficult and costly to obtain regulatory clearance or approval for future diagnostic tests.

Future Outlook

The company expects research and development expenses to increase to fund innovation and develop new clinically relevant tests, with an increasing portion allocated to biopharmaceutical service contracts. Sales and marketing expenses are also expected to increase with expansion of the sales force and marketing activities. General and administrative expenses are projected to increase due to headcount and public company operating costs. The company intends to monitor its common stock bid price and consider options, including a reverse stock split, to regain Nasdaq compliance. It will continue to evaluate the impact of new accounting standards and tax law changes (OBBBA).

Management Comments

• Our mission is to transform patient care and improve outcomes through personalized diagnostics that are timely, accessible, and address immediate clinical needs.
• We envision a world where patient disease is conquered through the guidance of personalized diagnostics.
• We believe our diagnostic tests help healthcare providers meaningfully improve lung disease diagnosis, treatment, and monitoring as well as lower the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures.
• We believe that no single technology can interrogate the complexity of the human disease state to help solve all clinical questions. For that reason, we employ a multi-omic approach to solving diagnostic challenges.
• While our Development Services revenue continues to grow, we benefit from these partnerships in ways that expand beyond revenue, continuously expanding our knowledge and biological understanding of multiple diseases and the rapidly evolving treatment and regulatory approval landscape.
• We intend to monitor the closing bid price of our common stock and will consider various options available to us if our common stock does not trade at a level to regain compliance with the Minimum Bid Price Requirement. These options include effecting a reverse stock split designed to increase the bid price of our common stock in an amount sufficient to regain compliance with the Minimum Bid Price Requirement.

Industry Context

Biodesix operates in the highly competitive and evolving diagnostic solutions industry, particularly focused on lung cancer and biopharmaceutical development services. The industry faces significant regulatory changes, with the FDA's recent efforts to regulate laboratory developed tests (LDTs) as medical devices, although a recent court ruling struck down this final rule. This creates a dynamic and uncertain regulatory environment for companies like Biodesix. The company's multi-omic approach and collaborations with institutions like MSK align with broader industry trends towards personalized medicine and advanced biomarker discovery.

Comparison to Industry Standards

• We believe we are the only company to offer two commercial blood-based tests (Nodify CDT and Nodify XL2) to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.
• Biodesix Development Services have been utilized by over 65 industry clients and academic partners, indicating a strong presence in the biopharmaceutical services sector.

Legal Proceedings

• The company is not presently a party to any legal proceedings that would individually or collectively have a material adverse effect on its business, results of operations, financial condition, or cash flows.
• Legal challenges have been filed in federal district court over the FDA's authority to regulate laboratory developed tests (LDTs) as medical devices, with a recent ruling striking down the FDA's final rule. This creates regulatory uncertainty for the company's LDTs.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises (ATM program) and significant risk to stock liquidity and market price due to the Nasdaq delisting notice.
• Employees are impacted by share-based compensation plans and the company's financial performance.
• Customers (healthcare providers and biopharmaceutical companies) benefit from continued diagnostic testing services and development capabilities, but could be affected by regulatory changes or financial instability.
• Creditors (Perceptive Credit Holdings IV, LP) have a secured interest in company assets and are subject to the company's compliance with debt covenants.

Next Steps

• Monitor the closing bid price of common stock and consider options, including a reverse stock split, to regain Nasdaq compliance by September 22, 2025.
• Complete study follow-up for all 5,000 patients in the INSIGHT study by 2026.
• Continue the CLARIFY study, a retrospective chart review of up to 4,000 patients, to confirm performance of Nodify CDT and Nodify XL2 tests.
• Continue collaboration with Memorial Sloan Kettering Cancer Center (MSK) under the master collaborative research agreement (MCRA) for oncology biomarker assays.
• Evaluate the impact of ASU 2023-09 (Income Taxes) and ASU 2024-03 (Disaggregation of Income Statement Expenses) on financial statements.
• Monitor additional guidance from the U.S. Department of the Treasury or the Internal Revenue Service regarding the One Big Beautiful Bill Act (OBBBA).

Key Dates

Recommendation

While Biodesix demonstrates solid revenue growth and improved gross margins, indicating operational progress, the increasing net loss in the most recent quarter and declining cash position are concerning. The Nasdaq delisting notice for minimum bid price non-compliance introduces significant uncertainty and risk to shareholder value and market liquidity. The ongoing regulatory ambiguity surrounding LDTs further complicates the outlook. A 'hold' recommendation acknowledges the company's growth potential in a critical diagnostic area and its strategic partnerships, but advises caution due to the immediate financial pressures, cash burn, and the critical need to resolve the Nasdaq listing issue and navigate regulatory changes. Investors should monitor these risks closely.

Keywords

Diagnostic Solutions, Lung Cancer, Blood-based Tests, Multi-omic, Proteomics, Genomics, Nodify Lung, Nodify CDT, Nodify XL2, GeneStrat, VeriStrat, IQLung, Biopharmaceutical Services, SEC Filing, 10-Q, Nasdaq Listing, FDA Regulation, LDTs, Clinical Trials, Oncology Biomarkers